A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject solely after viral steady state is reached an effective viral load-reducing amount of an IgG monoclonal antibody which (a) binds to a CCR5 chemokine receptor, (b) inhibits binding of HIV-1JR-FL gp120/sCD4 complex to a CCR5 receptor on the surface of a CD4−CCR5+ cell, and (c) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to thereby reduce the subject's HIV 1 viral load to 50% or less of the subject's viral load prior to administration of any of the antibody to the subject, wherein the monoclonal antibody is PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) or an antibody that cross-competes with monoclonal antibody PA14 for binding to the CCR5 receptor.
›2.↳ 1The method of claim 1, wherein the antibody is PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB-12610).d2
The method of claim 1, wherein the antibody is PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB-12610).
›3.↳ 1The method of claim 1, wherein after treatment, the subject's HIV1 viral load is reduced to 33% or less of the subject's HIV- 1 viral load prior to ad…d2
The method of claim 1, wherein after treatment, the subject's HIV1 viral load is reduced to 33% or less of the subject's HIV- 1 viral load prior to administering the antibody to the subject.
›4.↳ 1The method of claim 1, wherein after treatment, the subject's HIV-1 viral load is reduced to 10% or less of the subject's HIV-1 viral load prior to ad…d2
The method of claim 1, wherein after treatment, the subject's HIV-1 viral load is reduced to 10% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.
›5.↳ 1The method of claim 1, wherein the reduction of the subject's HIV-1 viral load is sustained for at least one day.d2+2
The method of claim 1, wherein the reduction of the subject's HIV-1 viral load is sustained for at least one day.
›6.↳ 5The method of claim 5, wherein the reduction is sustained for at least three days.d3
The method of claim 5, wherein the reduction is sustained for at least three days.
›7.↳ 5The method of claim 5, wherein the reduction is sustained for at least seven days.d3
The method of claim 5, wherein the reduction is sustained for at least seven days.
›8.↳ 1The method of claim 1, wherein the effective amount of the antibody is between 0.1 mg and 100 mg per kg body weight of the subject.d2+5
The method of claim 1, wherein the effective amount of the antibody is between 0.1 mg and 100 mg per kg body weight of the subject.
›9.↳ 8The method of claim 8, wherein the effective amount of the antibody is between 1 mg and 50 mg per kg body weight of the subject.d3+4
The method of claim 8, wherein the effective amount of the antibody is between 1 mg and 50 mg per kg body weight of the subject.
›10.↳ 9The method of claim 9, wherein the effective amount of the antibody is between 2 mg and 40 mg per kg body weight of the subject.d4+3
The method of claim 9, wherein the effective amount of the antibody is between 2 mg and 40 mg per kg body weight of the subject.
›11.↳ 10The method of claim 10, wherein the effective amount of the antibody is between 3 mg and 30 mg per kg body weight of the subject.d5+2
The method of claim 10, wherein the effective amount of the antibody is between 3 mg and 30 mg per kg body weight of the subject.
›12.↳ 11The method of claim 11, wherein the effective amount of the antibody is between 4 mg and 20 mg per kg body weight of the subject.d6+1
The method of claim 11, wherein the effective amount of the antibody is between 4 mg and 20 mg per kg body weight of the subject.
›13.↳ 12The method of claim 12, wherein the effective amount of the antibody is between 5 mg and 10 mg per kg body weight of the subject.d7
The method of claim 12, wherein the effective amount of the antibody is between 5 mg and 10 mg per kg body weight of the subject.
›14.↳ 1The method of claim 1, wherein the antibody is administered at least once per day.d2+1
The method of claim 1, wherein the antibody is administered at least once per day.
›15.↳ 14The method of claim 14, wherein the antibody is administered daily.d3
The method of claim 14, wherein the antibody is administered daily.
›16.↳ 1The method of claim 1, wherein the antibody is administered every other day.d2
The method of claim 1, wherein the antibody is administered every other day.
›17.↳ 1The method of claim 1, wherein the antibody is administered every 6 to 8 days.d2+1
The method of claim 1, wherein the antibody is administered every 6 to 8 days.
›18.↳ 17The method of claim 17, wherein the antibody is administered weekly.d3
The method of claim 17, wherein the antibody is administered weekly.
›19.↳ 1The method of claim 1, wherein the antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, orally or topically.d2
The method of claim 1, wherein the antibody is administered intravenously, subcutaneously, intramuscularly, intraperitoneally, orally or topically.
›20.↳ 1The method of claim 1, wherein the subject is a human being and the antibody is a humanized antibody.d2
The method of claim 1, wherein the subject is a human being and the antibody is a humanized antibody.
›21.↳ 1The method of claim 1, wherein the subject is a human being and the antibody is a human antibody.d2
The method of claim 1, wherein the subject is a human being and the antibody is a human antibody.
›22.↳ 1The method of claim 1, wherein the antibody is a chimeric antibody.d2
The method of claim 1, wherein the antibody is a chimeric antibody.
›23.↳ 1A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject solely after viral steady state is rea…d2
A method of reducing HIV-1 viral load in an HIV-1 infected subject which comprises administering to the subject solely after viral steady state is reached an effective viral load-reducing amount of the IgG monoclonal antibody of claim 1, wherein the antibody binds to an epitope which comprises amino acid residues in both the N-terminus (Nt) and in the second extracellular loop (ECL2) region of the CCR5 receptor.
